Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Cancer Prevention, Hereditary Genetics, and Epidemiology

Type: Poster Session

Time: Monday June 3, 1:15 PM to 4:15 PM

Location: Hall A

Burden of thrombocytopenia in adult cancer patients receiving chemotherapy.


Cancer Prevention, Hereditary Genetics, and Epidemiology

2019 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Session (Board #49)

J Clin Oncol 37, 2019 (suppl; abstr 1555)

Author(s): Gerald A. Soff, Jaime Shaw, Karynsa Kilpatrick, Andrea Marongiu, Joseph Park; Memorial Sloan Kettering Cancer Center, New York, NY; Amgen, San Diego, CA; Center for Observational Research, Amgen Inc, Thousand Oaks, CA; Uxbridge, London, United Kingdom; Amgen, Los Angeles, CA

Abstract Disclosures


Background: Thrombocytopenia is a common toxicity of chemotherapy, yet there are limited data on its occurrence in routine clinical practice. Methods: Using structured patient-level data from the Flatiron Health EHR-derived database, we assessed risk (3-month cumulative incidence) of chemotherapy-induced thrombocytopenia (CIT) in adult patients (2012-2017) based on platelet counts, overall and by each grade of CIT, cancer type, and chemotherapy regimen (Table); and the co-occurrence of other hematologic abnormalities. Results: Of 15,521 solid tumor patients who initiated chemotherapy, 13% had evidence of CIT within 3 months (platelet count <100x109/L), 4% had grade 3 (25 to <50x109/L) and 2% had grade 4 (<25x109/L) CIT. Of the solid tumors examined, incidence was highest in melanoma patients. In hematologic malignancies (N = 2,537), 3-month risk was even higher with nearly 30%, 16%, and 12% having any grade, grade 3 and 4 CIT, respectively; and the greatest risk being in multiple myeloma patients. Anthracycline-based regimens were associated with the highest risk of CIT (7% grade 3; 4% grade 4), followed by gemcitabine- and platinum-based regimens. Anemia often accompanied first evidence of CIT (49%); isolated thrombocytopenia occurred in 15%. Conclusions: This study provides a current snapshot of CIT risk in a large sample of adult patients undergoing chemotherapy in routine clinical practice, highlighting patients at highest risk for CIT and underscoring the complexity of managing cancer treatment.

Select chemotherapies and cancer types, N3-month Cumulative Incidence % (95% CI): OverallGrade 3Grade 4
Gemcitabine, 1,66215.8 (14.3, 17.4)5.5 (4.5, 6.7)2.5 (1.9, 3.2)
Platinum, 8,05113.6 (13.0. 14.2)4.3 (3.9, 4.7)2.1 (1.8, 2.5)
Anthracycline, 1,97216.4 (15.0, 18.0)7.1 (6.0, 8.4)3.6 (2.9, 4.4)
Taxane, 2,1166.6 (5.7, 7.7)2.0 (1.5, 2.5)0.8 (0.5, 1.3)
Multiple Myeloma, 64437.3 (34.2, 40.6)23.5 (20.8, 26.6)18.8 (16.4, 21.5)
Non-Hodgkin’s Lymphoma, 1,32124.4 (22.2, 26.7)13.2 (11.5, 15.0)9.1 (7.5, 11.0)
Melanoma, 5821.4 (14.7, 31.2)13.3 (6.8, 26.0)5.0 (1.8, 14.1)
All Hematologic Malignancies, 2,53728.2 (26.5, 30.0)16.3 (14.8, 17.9)12.4 (11.2, 13.8)
All Solid Tumors, 15,52112.8 (12.3, 13.4)4.2 (3.9, 4.6)1.9 (1.7, 2.1)

Other Abstracts in this Sub-Category:


1. Genome-wide association study using whole-genome sequencing to identify a novel locus associated with cardiomyopathy risk in adult survivors of childhood cancer: Utility of a two-stage analytic approach.

Meeting: 2019 ASCO Annual Meeting Abstract No: 1516 First Author: Yadav Sapkota
Category: Cancer Prevention, Hereditary Genetics, and Epidemiology - Epidemiology


2. Association between breast cancer mortality-to-incidence ratios and state health disparities in the United States.

Meeting: 2019 ASCO Annual Meeting Abstract No: 1548 First Author: Yu-Che Lee
Category: Cancer Prevention, Hereditary Genetics, and Epidemiology - Epidemiology


3. Contralateral breast cancer risk according to first breast cancer characteristics among United States women from 1992 to 2015.

Meeting: 2019 ASCO Annual Meeting Abstract No: 1549 First Author: Cody Ramin
Category: Cancer Prevention, Hereditary Genetics, and Epidemiology - Epidemiology